

PB 75 of 2024

National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 25 June 2024

Nikolai Tsyganov Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health and Aged Care

Contents

1 Name	1
2 Commencement	1
3 Authority	
4 Schedules	1
Schedule 1—Amendments commencing 1 July 2024	2
National Health (Minimum Stockholding) Determination 2023	2
Schedule 2—Amendments commencing 1 October 2024	15
National Health (Minimum Stockholding) Determination 2023	15
Schedule 3—Amendments commencing 1 December 2024	17
National Health (Minimum Stockholding) Determination 2023	17

i

1 Name

- (1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024.
- (2) This instrument may also be cited as PB 75 of 2024.

2 Commencement

(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information				
Column 1	Column 2	Column 3		
Provisions	Commencement	Date/Details		
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 July 2024.	1 July 2024		
2. Schedule 1	1 July 2024.	1 July 2024		
3. Schedule 2	1 October 2024.	1 October 2024		
4. Schedule 3	1 December 2024.	1 December 2024		

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 July 2024

National Health (Minimum Stockholding) Determination 2023

	ule 1 (table) mit:			
Aripiprazole	Tablet 10 mg	Oral	Aripic Aripiprazole	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand
2 Sched	ule 1 (table)			
О	mit:			
Atorvastatin	Tablet 10 mg (as calcium)	Oral	Atorvastatin GH	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand
Atorvastatin	Tablet 40 mg (as calcium)	Oral	Atorvastatin GH	between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand
3 Sched	ule 1 (table)			
А	fter:			
Atomoxetine	Capsule 80 mg (as hydrochloride)	Oral	APO-Atomoxetine	3 months stock by reference to usual demand
in	sert:			
Atorvastatin	Tablet 10 mg (as calcium)	Oral	Blooms the Chemist Atorvastatin	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
Atorvastatin	Tablet 20 mg (as calcium)	Oral	Blooms the Chemist Atorvastatin	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
Atorvastatin	Tablet 40 mg (as calcium)	Oral	Blooms the Chemist Atorvastatin	between 1 July 2024 and 31 August 2024—0months stock by reference to usual demand
Atorvastatin	Tablet 80 mg (as calcium)	Oral	Blooms the Chemist Atorvastatin	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand

\cap				
0	mit:			
Candesartan	Tablet containing candesartan cilexetil 16 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 32 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 4 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 8 mg	Oral	NOUMED CANDESARTAN	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand
Capecitabine	Tablet 150 mg	Oral	Capecitabine-DRLA	between 1 February 2024 and 30 June 2024—0 months
				stock by reference to usual demand
5 Sched	ule 1 (table)			
	ule 1 (table) fter:			
		Oral	Cal-500	
A Calcium	fter: Tablet, chewable, 500 mg (as	Oral	Cal-500	usual demand 6 months stock by reference to usual
A Calcium	fter: Tablet, chewable, 500 mg (as carbonate)	Oral Oral	Cal-500 Blooms the Chemist Candesartan	usual demand 6 months stock by reference to usual
A Calcium in	fter: Tablet, chewable, 500 mg (as carbonate) sert: Tablet containing candesartan cilexetil		Blooms the Chemist	usual demand 6 months stock by reference to usual PBS demand between 1 July 2024 and 31 August 2024—0 months stock by reference to
A Calcium in Candesartan	fter: Tablet, chewable, 500 mg (as carbonate) asert: Tablet containing candesartan cilexetil 16 mg Tablet containing candesartan cilexetil	Oral	Blooms the Chemist Candesartan Blooms the Chemist	usual demand 6 months stock by reference to usual PBS demand between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand between 1 July 2024 and 31 August 2024—0 months stock by reference to

4 Schedule 1 (table)

National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024

			stock by reference to usual demand
Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg	Oral	Blooms the Chemist Candesartan HCTZ 32/12.5	between 1 July 2024 and 31 August 2024— 0 months stock by reference to usual demand
Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg	Oral	Blooms the Chemist Candesartan HCTZ 32/25	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
Tablet 500 mg	Oral	Capecitabine-DRLA	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
e 1 (table)			
it:			
Powder for injection 1 g (as hydrochloride)	Injection	Omegapharm Pty Ltd	between 1 May 2024 and 31 May 2024—0 months stock by reference to usual demand
Powder for injection 2 g (as hydrochloride)	Injection	Omegapharm Pty Ltd	between 1 May 2024 and 31 May 2024—0 months stock by reference to usual demand
e 1 (table)			
· · · · ·			
Capsule 150 mg (as hydrochloride)	Oral	Clindamycin BNM	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand
e 1 (table)			
er:			
Oral liquid 2.5 mg per mL, 10 mL	Oral	Rivotril	6 months stock by reference to usual PBS demand
rt:			
Tablet 75 mg (as besilate)	Oral	BTC Clopidogrel	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
	candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg Tablet 500 mg e 1 (table) it: Powder for injection 1 g (as hydrochloride) Powder for injection 2 g (as hydrochloride) e 1 (table) it: Capsule 150 mg (as hydrochloride) e 1 (table) er: Oral liquid 2.5 mg per mL, 10 mL ert: Tablet 75 mg (as	candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg Tablet 500 mg Oral e 1 (table) it: Powder for injection 1 g (as hydrochloride) Powder for injection 2 g (as hydrochloride) Injection 2 g (as hydrochloride) e 1 (table) it: Capsule 150 mg (as hydrochloride) Cral Oral e 1 (table) er: Oral liquid 2.5 mg per mL, 10 mL rt: Tablet 75 mg (as Oral	candesartan cilexetil Candesartan HCTZ 32 mg with 32/12.5 hydrochlorothiazide 12.5 mg Tablet containing Oral Blooms the Chemist candesartan cilexetil 32/25 32 mg with 32/25 hydrochlorothiazide 23 mg Tablet containing Oral candesartan cilexetil 32/25 hydrochlorothiazide 25 mg Tablet 500 mg Oral Capecitabine-DRLA e 1 (table) it: Powder for injection 1 g (as hydrochloride) Injection Omegapharm Pty Ltd p (as hydrochloride) Injection Omegapharm Pty Ltd g (as hydrochloride) Injection Omegapharm Pty Ltd it: Capsule 150 mg (as Oral Nydrochloride) Oral Clindamycin BNM it: Capsule 150 mg (as Oral Nydrochloride) Oral Rivotril Rivotril e 1 (table) oral Rivotril Rivotril er: Oral liquid 2.5 mg Per mL, 10 mL Oral Rivotril

4

	After:	1 (table)			
Enalapril		Tablet containing enalapril maleate 5 mg	Oral	Malean	4 months stock by reference to usual demand
	insert:				
Entecavir		Tablet 0.5 mg (as monohydrate)	Oral	Entecavir Mylan	after 30 September 2024— 4 months stock by reference t usual demand of bo Entecavir Viatris ar Entecavir Mylan added together
10 Se	chedule	e 1 (table)			
	After:				
Escitalopram		Tablet 10 mg (as oxalate)	Oral	APX-Escitalopram	4 months stock by reference to usual demand
F '/ 1	insert		0.1		1 / 1 1 1 202
Escitalopram		Tablet 10 mg (as oxalate)	Oral	Blooms the Chemist Escitalopram	between 1 July 202 and 31 August 2024—0 months stock by reference t usual demand
11 Se	chedule	e 1 (table)			
	After:				
Escitalopram		Tablet 20 mg (as oxalate)	Oral	APX-Escitalopram	4 months stock by reference to usual demand
	insert	:			
Escitalopram		Tablet 20 mg (as oxalate)	Oral	Blooms the Chemist Escitalopram	between 1 July 202 and 31 August 2024—0 months stock by reference t usual demand
Ezetimibe		Tablet 10 mg	Oral	Blooms The Chemist Ezetimibe	between 1 July 202 and 31 July 2024 months stock by reference to usual demand
12 Se	chedule	e 1 (table)			
	After:				
Felodipine		Tablet 2.5 mg (extended release)	Oral	Plendil ER	2.5 months stock by reference to usual demand
	insert	:			
Fenofibrate		Tablet 145 mg	Oral	Blooms the Chemist Fenofibrate	between 1 July 2024 and 31 August

National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024

stock by reference to usual demand

13 Schedule 1 (table)

Omit:

Omit	:			
Fluorometholone	Eye drops 1 mg per mL, 5 mL	Application to the Eye	FML Liquifilm	2 months stock by reference to usual PBS demand
subst				
Fluorometholone	Eye drops 1 mg per mL, 5 mL	Application to the Eye	FML Liquifilm	between 1 July 2024 and 31 January 2025—0 months stock by reference to usual demand
14 Schedul	e 1 (table)			
After	:			
Fluorometholone	Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL	Application to the Eye	Flarex	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual PBS demand
insert	•			
Fluoxetine	Capsule 20 mg (as hydrochloride)	Oral	BTC Fluoxetine	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
15 Schedul	e 1 (table)			
After				
Galantamine	Capsule (prolonged release) 8 mg (as hydrobromide)	Oral	Gamine XR	3 months stock by reference to usual demand
insert	•			
Glimepiride	Tablet 1 mg	Oral	Amaryl	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
16 Schedul	e 1 (table)			
After				
Glucose and ketone indicator-urine	Test strips, 50 (Keto-Diastix)	For External Use	Keto-Diastix	4 months stock by reference to usual PBS demand
insert				
Granisetron	Concentrated injection 3 mg (as hydrochloride) in 3 mL	Injection	Granisetron Kabi	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand

National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024

17 Schedul After	· · · ·			
Insect allergen extract-yellow jacket venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Yellow Jacket Venom	6 months stock by reference to usual PBS demand
inser	t:			
Irbesartan	Tablet 150 mg	Oral	Blooms the Chemist Irbesartan	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
Irbesartan	Tablet 75 mg	Oral	Avapro	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
Irbesartan	Tablet 75 mg	Oral	Blooms the Chemist Irbesartan	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
Irbesartan with hydrochlorothiazide	Tablet 150 mg-12.5 mg	Oral	AVSARTAN HCT 150/12.5	4 months stock by reference to usual demand
18 Schedul	le 1 (table)			
After				
Latanoprost with timolol	Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL	Application to the Eye	APO-Latanoprost/Ti molol 0.05/5	2.5 months stock by reference to usual demand
inser	t:			
Leflunomide	Tablet 10 mg	Oral	Arabloc	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
Lercanidipine	Tablet containing lercanidipine hydrochloride 10 mg	Oral	BTC Lercanidipine	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
Lercanidipine	Tablet containing lercanidipine hydrochloride 20 mg	Oral	BTC Lercanidipine	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand

National Health (Minimum Stockholding) Amendment Determination (No. 6) 2024

	redule 1 (table) After:			
Meloxicam	Tablet 7.5 mg	Oral	MELOBIC	4 months stock by reference to usual demand
	insert:			
Metformin	Tablet (extended release) containing metformin hydrochloride 1 g	Oral	Blooms the Chemist Metformin XR 1000	between 1 July 2024 and 31 July 2024—0 months stock by reference to usual demand
Metformin	Tablet (extended release) containing metformin hydrochloride 500 mg	Oral	Blooms the Chemist Metformin XR 500	between 1 July 2024 and 31 July 2024—0 months stock by reference to usual demand
20 Sch	edule 1 (table)			
	Omit:			
Morphine	Tablet containing morphine sulfate pentahydrate 30 mg	Oral	Anamorph	3 months stock by reference to usual demand
21 Sch	edule 1 (table)			
	After:			
Norfloxacin	Tablet 400 mg	Oral	APO-Norfloxacin	2.5 months stock by reference to usual demand
Olanzapine	Insert: Tablet 10 mg	Oral	NOUMED	between 1 July 2024
Glanzaphie	rablet to hig	Grai	OLANZAPINE	and 31 August 2024—0 months stock by reference to usual demand
22 Sch	edule 1 (table)			
	After:			
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	Zypine ODT	 (a) between February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral; (b) between 1 October 2024 and 31 March

					2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together.
Olanzapi	insert	Tablet 2.5 mg	Oral	NOUMED	between 1 July 2024
-		-		OLANZAPINE	and 31 August 2024—0 months stock by reference to usual demand
2	23 Schedule After:				
Olanzapi		Tablet 20 mg (orally	Oral	Zypine ODT	(a) between
		disintegrating)			 (a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the

				pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together
Olanzapine	insert: Tablet 5 mg	Oral	NOUMED OLANZAPINE	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
	edule 1 (table) After:			
Olanzapine	Tablet 5 mg (orally disintegrating)	Oral	Zypine ODT	 (a) between February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral; (b) between October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together
	insert:			.
Olanzapine	Tablet 7.5 mg	Oral	NOUMED OLANZAPINE	between 1 July 2024 and 31 August 2024—0 months

10

stock by reference to usual demand

25 Schedule 1 (table) After: Periciazine Tablet 2.5 mg Oral Neulactil 6 months stock by reference to usual PBS demand insert: Perindopril Tablet containing Oral BTC Perindopril between 1 July 2024 perindopril erbumine and 31 August 2 mg 2024—0 months stock by reference to usual demand 26 Schedule 1 (table) After: (a) between 1 July Perindopril Tablet containing Indosyl Mono 2 Oral 2023 and perindopril erbumine 31 December 2 mg 2023—4 months stock by reference to usual demand (b) after 31 December 2023—5 months stock by reference to usual demand insert: Perindopril Tablet containing Oral BTC Perindopril between 1 July 2024 perindopril erbumine and 31 August 2024—0 months 4 mg stock by reference to usual demand 27 Schedule 1 (table) After: Perindopril Indosyl Mono 4 (a) between 1 July Tablet containing Oral 2023 and perindopril erbumine 31 December 4 mg 2023-4.5 months stock by reference to usual demand (b) after 31 December 2023-5.5 months stock by reference to usual demand

	ert:	Oral	DTC Domin dommil	hatwaan 1 July 202
Perindopril	Tablet containing perindopril erbumine 8 mg	Oral	BTC Perindopril	between 1 July 202 and 31 August 2024—0 months stock by reference t usual demand
28 Sched	ule 1 (table)			
Af	ter:			
Pregabalin	Capsule 300 mg	Oral	Cipla Pregabalin	between 1 February 2024 and 31 July 2024—0 months stock by reference t usual demand
	ert:			
Pregabalin	Capsule 75 mg	Oral	Blooms the Chemist Pregabalin	between 1 July 202 and 31 August 2024—0 months stock by reference t usual demand
29 Sched	ule 1 (table)			
Af	ter:			
Risperidone	Tablet 3 mg	Oral	Rispa	3 months stock by reference to usual demand
ins	ert:			
Rosuvastatin	Tablet 10 mg (as calcium)	Oral	Blooms the Chemist Rosuvastatin	between 1 July 202 and 31 August 2024—0 months stock by reference t usual demand
Rosuvastatin	Tablet 20 mg (as calcium)	Oral	Blooms the Chemist Rosuvastatin	between 1 July 202 and 31 August 2024—0 months stock by reference t usual demand
Rosuvastatin	Tablet 40 mg (as calcium)	Oral	Blooms the Chemist Rosuvastatin	between 1 July 202 and 31 August 2024—0 months stock by reference t usual demand
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	Blooms the Chemist Rosuvastatin	between 1 July 202 and 31 August 2024—0 months stock by reference t usual demand

	lule 1 (table) nit:			
Roxithromycin	Tablet 150 mg	Oral	Roximycin	between 1 May 2024 and 30 June 2024—0 months stock by reference to usual demand
31 Sched	lule 1 (table)			
Or	nit:			
Roxithromycin	Tablet 300 mg	Oral	Roximycin	between 1 May 2024 and 30 June 2024—0 months stock by reference to usual demand
32 Sched	lule 1 (table)			
Or	nit:			
Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by Mouth	Asmol CFC-Free with dose counter	between 1 January 2024 and 30 June 2024—0 months stock by reference to usual demand
Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by Mouth	Zempreon CFC-Free with dose counter	between 1 January 2024 and 30 June 2024—0 months stock by reference to usual demand
33 Sched	lule 1 (table)			
_	nit:			
Topiramate	Tablet 100 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand
34 Sched	lule 1 (table)			
Or	nit:			
Topiramate	Tablet 200 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand

	ıle 1 (table)			
Omi	it:			
Topiramate	Tablet 25 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024— 0 months stock by reference to usual demand
36 Schedu	ile 1 (table)			
Omi	it:			
Topiramate	Tablet 50 mg	Oral	NOUMED TOPIRAMATE	between 1 April 2024 and 30 June 2024—0 months stock by reference to usual demand
37 Schedu	ıle 1 (table)			
Omi				
Triglycerides, medium chain	Oral liquid 225 mL, 15 (K.Quik)	Oral	K.Quik	0 months stock by reference to usual PBS demand
38 Schedu	ıle 1 (table)			
After:				
Valproic acid	Tablet, crushable, containing sodium valproate 100 mg	Oral	Epilim	4 months stock by reference to usual PBS demand
insert:				
Venlafaxine	Capsule (modified release) 150 mg (as hydrochloride)	Oral	Blooms the Chemist Venlafaxine XR	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand
Venlafaxine	Capsule (modified release) 75 mg (as hydrochloride)	Oral	Blooms the Chemist Venlafaxine XR	between 1 July 2024 and 31 August 2024—0 months stock by reference to usual demand

Schedule 2—Amendments commencing 1 October 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule	l (table)			
Omit:				
Acarbose	Tablet 100 mg	Oral	Acarbose Viatris	4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together
2 Schedule	l (table)			
Omit:				
Dosulepin	Tablet containing dosulepin hydrochloride 75 mg	Oral	Dosulepin Viatris 75	6 months stock by reference to usual demand of both Dosulepin Viatris 75 and Dosulepin Mylan added together
3 Schedule	l (table)			
Omit:				
Lamivudine with zidovudine	Tablet 150 mg-300 mg	Oral	Lamivudine/Zidovud ine Viatris 150/300	after 31 May 2024— 4 months stock by reference to usual demand of both Lamivudine/Zidovud ine Viatris 150/300 and Lamivudine 150 mg + Zidovudine 300 mg Alphapharm added together
4 Schedule	l (table)			
Omit:				
Moxonidine	Tablet 200 micrograms	Oral	Moxonidine Viatris	4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together
Moxonidine	Tablet 400 micrograms	Oral	Moxonidine Viatris	4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together

5 Schedule 1 (table)

Omit:

	01111				
	Paraffin with retinol palmitate	Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g	Application to the Eye	VitA-POS	between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand
	6 Schedule	1 (table)			
Omit:					
	Valganciclovir	Tablet 450 mg (as hydrochloride)	Oral	Valganciclovir Viatris	4 months stock by reference to usual demand of both Valganciclovir Viatris and Valganciclovir Mylan added together

Schedule 3—Amendments commencing 1 December 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

After	:			
Metronidazole	Suppositories 500 mg, 10	Rectal	Flagyl	6 months stock by reference to usual PBS demand
insert	:			
Mifepristone and misoprostol	Pack containing 1 tablet mifepristone 200 mg and 4 tablets misoprostol 200 micrograms	Oral	MS-2 Step	6 months stock by reference to usual PBS demand
2 Schedule	1 (table)			
After	:			
Valganciclovir	Powder for oral solution 50 mg (as hydrochloride) per mL, 100 mL	Oral	Valcyte	4 months stock by reference to usual PBS demand
insert:				
Valine with carbohydrate	Sachets of oral powder 4 g containing 1 g valine, 30 (Valine 1000)	Oral	Valine 1000	6 months stock by reference to usual PBS demand
Valine with carbohydrate	Sachets of oral powder 4 g containing 50 mg valine, 30 (Valine 50)	Oral	Valine 50	6 months stock by reference to usual PBS demand